(RTTNews) - BridgeBio Pharma, Inc. (BBIO) reported topline results from month 12 of ATTRibute-CM, an ongoing phase 3 study investigating acoramidis for the treatment of symptomatic transthyretin amyloid cardiomyopathy. ATTRibute-CM did not meet its primary endpoint at month 12. The company noted that ATTRibute-CM independent data monitoring committee recommended continuing the study based on unblinded data reviews.
"This result is disappointing and baffling. I am, along with many others, searching for answers regarding the 6MWD," said Neil Kumar, founder and CEO of BridgeBio.
BridgeBio said it is well-capitalized through the completion of ATTRibute-CM and remains on track to deliver on additional catalysts in 2022 and 2023.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
